Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment
- 1 November 1999
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 58 (Supplement), i61-i64
- https://doi.org/10.1136/ard.58.2008.i61
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Endoscopic and histological healing with infliximab anti–tumor necrosis factor antibodies in Crohn's disease: A European multicenter trialGastroenterology, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993